A Cost-Effectiveness Analysis of Axitinib and Sorafenib for 2nd Line Treatment of Advanced Renal Cell Carcinoma After Failure of Cytokines in the United States

Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.500
https://www.valueinhealthjournal.com/article/S1098-3015(13)02405-4/fulltext
Title : A Cost-Effectiveness Analysis of Axitinib and Sorafenib for 2nd Line Treatment of Advanced Renal Cell Carcinoma After Failure of Cytokines in the United States
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02405-4&doi=10.1016/j.jval.2013.08.500
First page : A410
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 482
Categories :
Tags :
Regions :
ViH Article Tags :